← All trials
NCT04709705
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2021
- Primary completion
- Mar 31, 2023
- Completion date
- Apr 30, 2023
- First posted
- Jan 14, 2021
- Last posted
- Sep 14, 2021
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Cellphire, Inc.Lead sponsor
- Cellphire, Inc.Study director
- University of OklahomaOverall official - principal investigator
- United States ArmyCollaborator
- MaineGeneral HealthOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.